ERG Induces Epigenetic Activation of Tudor Domain-Containing Protein 1 (TDRD1) in ERG Rearrangement-Positive Prostate Cancer

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Kacprzyk, Lukasz A ^a,d   Laible, Mark ^a   Andrasiuk, Tatjana ^a   Brase, Jan C ^a,e   Börno, Stefan T ^b,c   Fälth, Maria ^a   Kuner, Ruprecht ^a   Lehrach, Hans ^b   Schweiger, Michal R ^b   Sültmann, Holger ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d UNIVERSITY OF GEORGIA   (United States)

^e Sividon Diagnostics GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR ERG;

ARTICLE; CANCER CELL; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; EPIGENETICS; ERG GENE; EXON; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE REARRANGEMENT; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROTEIN DEPLETION; TDRD1 GENE; TESTIS CANCER; TRANSCRIPTION INITIATION; TUMOR GENE;

CARRIER PROTEINS; CELL LINE, TUMOR; DNA METHYLATION; EPIGENOMICS; HUMANS; MALE; PROSTATIC NEOPLASMS; SERINE ENDOPEPTIDASES; TRANS-ACTIVATORS;

EID: 84875509226     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059976     Document Type: Article

References (64)

1. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648.
2. Mehra R, Tomlins SA, Shen R, Nadeem O, Wang L, et al. (2007) Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Modern Pathology 20: 538-544.
3. Rubin MA, Maher CA, Chinnaiyan AM, (2011) Common gene rearrangements in prostate cancer. Journal of Clinical Oncology 29: 3659-3668.
4. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, et al. (2010) Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia (New York, NY) 12: 590.
5. Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, et al. (2011) Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. The American journal of surgical pathology 35: 1014.
6. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, et al. (2011) ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clinical Cancer Research 17: 5878-5888.
7. Clark JP, Cooper CS, (2009) ETS gene fusions in prostate cancer. Nature Reviews Urology 6: 429-439.
8. Loughran SJ, Kruse EA, Hacking DF, de Graaf CA, Hyland CD, et al. (2008) The transcription factor Erg is essential for definitive hematopoiesis and the function of adult hematopoietic stem cells. Nature immunology 9: 810-819.
9. Minner S, Luebke AM, Kluth M, Bokemeyer C, Jänicke F, et al. (2012) High level of Ets-related gene expression has high specificity for prostate cancer: a tissue microarray study of 11 483 cancers. Histopathology 61(3): 445-453.
10. Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, et al. (2010) An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer cell 17: 443-454.
11. Sun C, Dobi A, Mohamed A, Li H, Thangapazham R, et al. (2008) TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 27: 5348-5353.
12. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, et al. (2008) Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. Journal of the National Cancer Institute 100: 815-825.
13. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, et al. (2010) FZD4 as a Mediator of ERG Oncogene-Induced WNT Signaling and Epithelial-to-Mesenchymal Transition in Human Prostate Cancer Cells. Cancer research 70: 6735-6745.
14. Tomlins SA, Laxman B, Varambally S, Cao X, Yu J, et al. (2008) Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (New York, NY) 10: 177.
15. Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, et al. (2011) Mechanistic rationale for inhibition of poly (ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer cell 19: 664-678.
16. Brase JC, Johannes M, Mannsperger H, Fälth M, Metzger J, et al. (2011) TMPRSS2-ERG-specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling. BMC cancer 11: 507.
17. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer cell 18: 11-22.
18. Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, et al. (2008) Absence of TMPRSS2: ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Modern Pathology 21: 1451-1460.
19. King JC, Xu J, Wongvipat J, Hieronymus H, Carver BS, et al. (2009) Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nature genetics 41: 524-526.
20. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, et al. (2009) Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nature genetics 41: 619-624.
21. Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, et al. (2011) Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome research 21: 1028-1041.
22. Börno ST, Fischer A, Kerick M, Fälth M, Laible M, et al. (2012) Genome-wide DNA methylation events in TMPRSS2: ERG fusion negative prostate cancers implicate an EZH2 dependent mechanism with miRNA-26a hypermethylation. Cancer Discovery. doi: 10.1158/2159-8290.CD-12-0041.
23. Jhavar S, Brewer D, Edwards S, Kote-Jarai Z, Attard G, et al. (2009) Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU international 103: 1256-1269.
24. Wang J, Cai Y, Shao L, Siddiqui J, Palanisamy N, et al. (2011) Activation of NF-κB by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. Cancer research 71: 1325-1333.
25. Wang PJ, McCarrey JR, Yang F, Page DC, (2001) An abundance of X-linked genes expressed in spermatogonia. Nature genetics 27: 422-426.
26. Loriot A, Boon T, De Smet C, (2003) Five new human cancer-germline genes identified among 12 genes expressed in spermatogonia. International journal of cancer 105: 371-376.
27. Reuter M, Chuma S, Tanaka T, Franz T, Stark A, et al. (2009) Loss of the Mili-interacting Tudor domain-containing protein-1 activates transposons and alters the Mili-associated small RNA profile. Nature structural & molecular biology 16: 639-646.
28. Huang HY, Houwing S, Kaaij LJT, Meppelink A, Redl S, et al. (2011) Tdrd1 acts as a molecular scaffold for Piwi proteins and piRNA targets in zebrafish. The EMBO Journal 30: 3298-3308.
29. Chuma S, Hosokawa M, Kitamura K, Kasai S, Fujioka M, et al. (2006) Tdrd1/Mtr-1, a tudor-related gene, is essential for male germ-cell differentiation and nuage/germinal granule formation in mice. Proceedings of the National Academy of Sciences 103: 15894-15899.
30. Wang J, Cai Y, Ren C, Ittmann M, (2006) Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer research 66: 8347.
31. Clark J, Merson S, Jhavar S, Flohr P, Edwards S, et al. (2006) Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 26: 2667-2673.
32. Wittig-Blaich SM, Kacprzyk LA, Eismann T, Bewerunge-Hudler M, Kruse P, et al. (2011) Matrix-dependent regulation of AKT in hepsin-overexpressing PC3 prostate cancer cells. Neoplasia (New York, NY) 13: 579.
33. Haan C, Behrmann I, (2007) A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background. Journal of immunological methods 318: 11-19.
34. Rohde C, Zhang Y, Reinhardt R, Jeltsch A, (2010) BISMA-Fast and accurate bisulfite sequencing data analysis of individual clones from unique and repetitive sequences. BMC bioinformatics 11: 230.
35. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, et al. (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (New York, NY) 9: 166.
36. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, et al. (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487: 239-243.
37. Baldus CD, Liyanarachchi S, Mrózek K, Auer H, Tanner SM, et al. (2004) Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. Proceedings of the National Academy of Sciences of the United States of America 101: 3915.
38. Baldus CD, Burmeister T, Martus P, Schwartz S, Gökbuget N, et al. (2006) High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. Journal of Clinical Oncology 24: 4714-4720.
39. Tsuzuki S, Taguchi O, Seto M, (2011) Promotion and maintenance of leukemia by ERG. Blood 117: 3858-3868.
40. Salek-Ardakani S, Smooha G, de Boer J, Sebire NJ, Morrow M, et al. (2009) ERG is a megakaryocytic oncogene. Cancer research 69: 4665.
41. Li Z, Huang H, Li Y, Jiang X, Chen P, et al. (2012) Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically-abnormal AML. Blood 119(10): 2314-2324.
42. Sorensen PHB, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, et al. (1994) A second Ewing's sarcoma translocation, t (21; 22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nature genetics 6: 146-151.
43. Jeon IS, Davis JN, Braun BS, Sublett JE, Roussel MF, et al. (1995) A variant Ewing's sarcoma translocation (7; 22) fuses the EWS gene to the ETS gene ETV1. Oncogene 10: 1229.
44. Zucman J, Melot T, Desmaze C, Ghysdael J, Plougastel B, et al. (1993) Combinatorial generation of variable fusion proteins in the Ewing family of tumours. The EMBO Journal 12: 4481.
45. Hart AH, Corrick CM, Tymms MJ, Hertzog PJ, Kola I, (1995) Human ERG is a proto-oncogene with mitogenic and transforming activity. Oncogene 10: 1423-1430.
46. Cooper A, van Doorninck J, Ji L, Russell D, Ladanyi M, et al. (2011) Ewing tumors that do not overexpress BMI-1 are a distinct molecular subclass with variant biology: a report from the Children's Oncology Group. Clinical Cancer Research 17: 56-66.
47. Postel-Vinay S, Véron AS, Tirode F, Pierron G, Reynaud S, et al. (2012) Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nature genetics 44(3): 323-327.
48. De Smet C, Loriot A, Boon T, (2004) Promoter-dependent mechanism leading to selective hypomethylation within the 5′ region of gene MAGE-A1 in tumor cells. Molecular and cellular biology 24: 4781-4790.
49. Deaton AM, Bird A, (2011) CpG islands and the regulation of transcription. Genes & development 25: 1010-1022.
50. Stresemann C, Lyko F, (2008) Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. International journal of cancer 123: 8-13.
51. Singal R, van Wert J, Bashambu M, (2001) Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. Cancer research 61: 4820.
52. Aravin AA, Hannon GJ, Brennecke J, (2007) The Piwi-piRNA pathway provides an adaptive defense in the transposon arms race. Science 318: 761-764.
53. O'Donnell KA, Boeke JD, (2007) Mighty Piwis defend the germline against genome intruders. Cell 129: 37-44.
54. Girard A, Sachidanandam R, Hannon GJ, Carmell MA, (2006) A germline-specific class of small RNAs binds mammalian Piwi proteins. Nature 442: 199-202.
55. Malone CD, Brennecke J, Dus M, Stark A, McCombie WR, et al. (2009) Specialized piRNA pathways act in germline and somatic tissues of the Drosophila ovary. Cell 137: 522-535.
56. Das PP, Bagijn MP, Goldstein LD, Woolford JR, Lehrbach NJ, et al. (2008) Piwi and piRNAs Act Upstream of an Endogenous siRNA Pathway to Suppress Tc3 Transposon Mobility in the Caenorhabditis elegans Germline. Molecular cell 31: 79-90.
57. Siomi MC, Sato K, Pezic D, Aravin AA, (2011) PIWI-interacting small RNAs: the vanguard of genome defence. Nature Reviews Molecular Cell Biology 12: 246-258.
58. Shoji M, Tanaka T, Hosokawa M, Reuter M, Stark A, et al. (2009) The TDRD9-MIWI2 complex is essential for piRNA-mediated retrotransposon silencing in the mouse male germline. Developmental cell 17: 775-787.
59. Sasaki T, Shiohama A, Minoshima S, Shimizu N, (2003) Identification of eight members of the Argonaute family in the human genome. Genomics 82: 323-330.
60. Jhavar S, Reid A, Clark J, Kote-Jarai Z, Christmas T, et al. (2008) Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays. The Journal of molecular diagnostics: JMD 10: 50.
61. Paulo P, Ribeiro FR, Santos J, Mesquita D, Almeida M, et al. (2012) Molecular Subtyping of Primary Prostate Cancer Reveals Specific and Shared Target Genes of Different ETS Rearrangements. Neoplasia (New York, NY) 14: 600.
62. Huttlin EL, Jedrychowski MP, Elias JE, Goswami T, Rad R, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143: 1174-1189.
63. Stadler MB, Murr R, Burger L, Ivanek R, Lienert F, et al. (2011) DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature 480: 490-495.
64. Heyn H, Ferreira HJ, Bassas L, Bonache S, Sayols S, et al. (2012) Epigenetic Disruption of the PIWI Pathway in Human Spermatogenic Disorders. PloS one 7: e47892.